SPSukanya Priyadarshini

Sukanya Priyadarshini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sukanya Priyadarshini has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multidisciplinary Care Model for Differences in Sex Development: An Implementation Research Study

    by Sukanya Priyadarshini, Ankesh Singh, Kaushal Kulkarni, Devendra Kumar Yadav, Rajesh Sagar, Rajni Sharma, Minu Bajpai, Vandana Jain

    Objective: To initiate a multidisciplinary care model for patients with differences in sex development (MD‐DSD), assess its implementation, and evaluate changes in perceived quality of care following implementation among parents and health‐care providers (HCPs). Design: Implementation research. Setting: Tertiary care Institute at New Delhi. Patients: Patients aged 0–22 years with DSD, receiving care in single‐specialty clinics at the Institute. Interventions: A core MD‐DSD team comprising specialists from Paediatric Endocrinology, Paediatric Surgery and Psychiatry was formed. Multidisciplinary clinics were conducted monthly, and board meetings for difficult cases were held bi‐monthly, with participation from all core and requisite allied specialties. Main Outcome Measures: The primary outcome was successful implementation of MD‐DSD clinics and board meetings, defined by representation from all three core specialties. Secondary outcomes included changes in the Perceived Quality‐of‐Care Questionnaire (PQCQ) scores (administered to parents at baseline and after attending two clinics, score range: 9‐45), and perceptions of participating HCPs at study completion. Results: Over 28 months, 28 clinics and 13 meetings were held. A total of 188 patients (46,XX DSD, 69; 46,XY DSD, 104; and sex chromosome DSD, 15) attended the MD‐DSD clinics; and 44 of these were also reviewed in MD‐DSD meetings, predominantly for concerns relating to gender of rearing and decision on surgical intervention. Participation from all core specialties was present in 26 (93%) clinics and 12 (92%) meetings. The PQCQ scores ( N = 79) improved from 32.2 ± 5.7 to 36.4 ± 4.5 ( p < 0.001), contributed chiefly by improved parent knowledge and attention to psychosocial needs. The participating HCPs ( N = 12/15) believed that the model was sustainable. Conclusions: The MD‐DSD care model was feasible and demonstrated favourable perceived sustainability, with improvement in the perceived quality of care reported by both parents and HCPs.

  • Congenital Adrenal Hyperplasia due to Proximal Steroidogenic Defects: A Single‐Centre Experience From New Delhi

    by Sukanya Priyadarshini, Priyanka Gupta, Avadhesh Verma, Rajni Sharma, Vandana Jain

    Background: Variants in STAR , encoding Steroidogenic Acute Regulatory (StAR) protein, and CYP11A1 , encoding the cholesterol Side‐Chain Cleavage (SCC) enzyme, result in proximal steroidogenic defects. These are classically described as presenting with neonatal‐onset primary adrenal insufficiency, with the additional finding of sex reversal in 46,XY newborns. However, the phenotypic spectrum is much wider. The present study aimed at describing the phenotypic heterogeneity and genotypes of patients with STAR and CYP11A1 variants followed up at a tertiary care centre in India. Methods: Hospital records of all patients with variants in STAR and CYP11A1 who were followed up at the Paediatric Endocrinology division of a tertiary care hospital between January 2018 and January 2026 were reviewed for clinical details and genotypes. Results: Variants in STAR and CYP11A1 were identified in four patients each. Among patients with variants in STAR , two had homozygous pathogenic/likely pathogenic variants, while two had two heterozygous variants; phase undetermined [of which one was a variant of uncertain significance (VUS)]. The presenting features were salt‐wasting crisis ( n = 3, at ages 2 years, 5 years and Day 15, respectively) and atypical genitalia ( n = 1). Among patients with variants in CYP11A1 , one had two heterozygous variants; phase undetermined (of which one was a VUS), while three had homozygous VUSs. The presentation ranged from adrenal crisis ( n = 1, at 3.8 years) and salt‐wasting crisis ( n = 1, at 10 months) to progressive hyperpigmentation ( n = 2, at ages 6.5 years and 21.9 years, respectively). None of the patients had genital ambiguity, while one patient presented with 46,XY sex reversal. Conclusion: The present study highlights the wide phenotypic spectrum associated with STAR and CYP11A1 variants, ranging from classical neonatal salt‐wasting crisis with 46,XY sex reversal, to isolated primary adrenal insufficiency, or isolated undervirilisation, with later emergence of gluco‐ and mineralocorticoid deficiency.

  • Optimizing Adult Height in Familial Male-Limited Precocious Puberty: A Case Report

    by Sukanya Priyadarshini, Shreyash Gandhi, Konpal Paharia, Rajni Sharma


  • Clinical Characterization and Molecular Profiling by Targeted Next‐Generation Sequencing in a Large Indian Cohort With 46,XY Differences in Sex Development

    by Vandana Jain, Sukanya Priyadarshini, Rajni Sharma, Anil Kumar, Shilpa Sharma, Palany Raghupathy, Ralf Werner, Olaf Hiort, Mohammed Faruq

    Background: 46,XY differences in sex development (DSD) comprise a heterogeneous group of conditions. Molecular diagnosis guides management by giving insights into the pathophysiology of sex development, reproduction, tumour formation and extragenital issues. Methods: Children with 46,XY DSD from a tertiary hospital in India underwent comprehensive assessment and stepwise genetic testing. Targeted testing for SRD5A2 and AR was performed in cases with suspected 5α‐reductase type 2 (5αR2) deficiency/androgen insensitivity syndrome (AIS). For all other patients, and those without variants in SRD5A2 or AR on Sanger sequencing, NGS using a targeted 155‐gene panel was performed. Longitudinal clinical data was also collated. Results: One hundred and forty‐seven children with 46,XY DSD with a median (interquartile range) age of 3.8 (1.4, 10.6) years were enrolled. Provisional clinical diagnoses were 5αR2 deficiency/AIS ( n = 83, 56.5%), gonadal dysgenesis ( n = 31, 21%), testosterone biosynthetic defect ( n = 11, 7.5%) and others ( n = 22, 15%) based on clinical, biochemical and radiological assessment. Sequential single gene testing for SRD5A2 and AR performed in 75 patients with a clinical diagnosis of 5αR2 deficiency/AIS identified pathogenic/likely pathogenic variants in 44 subjects. NGS in the remaining 103 children revealed pathogenic/likely pathogenic variants in 20 subjects across 12 genes, with NR5A1 being the most frequent (7/103). Four subjects had variants of uncertain significance (VUS) deemed possibly pathogenic due to good genotype‐phenotype correlation. Overall, 68/147 (46%) achieved a molecular diagnosis in this cohort. Conclusion: Sanger sequencing followed by NGS could provide molecular diagnosis in 46% of this Indian cohort with 46,XY DSD . SRD5A2 , AR and NR5A1 were the most frequently implicated genes.


  • Open Access

    Peripheral Precocious Puberty in a Girl with hCG-Secreting Suprasellar Germ Cell Tumor

    by Sukanya Priyadarshini, Priyanka Gupta, Vandana Jain


  • Open Access

    Myxedema Coma in Pediatric Patients

    by Sukanya Priyadarshini, Arushi Rai, Praveen George Paul, Rajni Sharma, Vandana Jain

  • Profile of monogenic diabetes: a Pan-India study

    by Viswanathan Mohan, Anandakumar Amutha, Ramasamy Aarthy, Subramani Poongothai, Coimbatore Subramanian Shanthirani, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Sekar Kanthimathi, Dhanasekaran Bodhini, Phillips Routray, et al.


  • Submicroscopic copy number variants in Indian children with gene panel negative 46, XY Gonadal Dysgenesis: An exploratory study using comparative genomic hybridization

    by Sukanya Priyadarshini, Uzma Shamim, Anil Kumar, Rajni Sharma, Mohammed Faruq, Vandana Jain

    Background: 46, XY disorders of sex development (DSD) are a group of highly heterogeneous conditions in which the molecular etiology remains unknown in a significant proportion of patients, even with massive parallel sequencing. Clinically significant copy number variants (CNVs) are identified in 20−30% of cases, particularly among those with gonadal dysgenesis (GD) and no molecular diagnosis. Methods: Fourteen patients with 46, XY DSD due to GD in whom no pathogenic/likely pathogenic variants were found on next‐generation sequencing using a targeted panel of 155 genes were screened for clinically significant CNVs using Affymetrix Comparative Genomic Hybridization (CGH). Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (DECIPHER) and ClinVar were searched for matching genotypes and phenotypes, and chromosomal regions were screened for genes with known or potential association with GD. Results: Significant CNVs were identified in 6 (43%) of 14 patients with 46, XY GD. A previously unreported 19p13.3 duplication was found in three patients. This CNV was associated with GD based on overlapping CNV regions from previous studies and databases; and the inclusion of CIRBP , a candidate gene implicated in GD. CNVs involving WT1 (11p15) and SOX8 (16p13.3) were also identified. Conclusions: CGH was helpful in pointing toward the molecular etiology in a significant proportion of patients with “idiopathic” 46, XY GD. However, establishing causality will require additional evidence including functional studies.